Leveraging its close collaboration with the American Society of Gene & Cell Therapy (ASGCT), this congress brings together top global scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions to comprehensively showcase the latest scientific achievements, technological applications, market access information, and high-quality collaborative projects in the field of cell and gene therapy. The event will establish a premium platform for in-depth exchange and cooperation between China’s CGT industry and the global industrial chain.

As a global leader in cell and gene therapy services, Lonza will actively participate in this conference and showcase its advanced products and technologies supporting CGT research, development, and manufacturing at Booth A06, including but not limited to:

• Fully Closed Cell Therapy Manufacturing Platform

• Cell Culture Medium

• Transfection Technologies and Platforms

• Primary Cells

• Mycoplasma Testing and Endotoxin Testing

• GMP Production and Quality Management Software

Among these, the highly anticipated new Lonza electroporation module—the 4D-Nucleofector LV PRO—has broken through the efficiency bottleneck of non-viral delivery in large-volume processing. With its superior consistency, flexibility, and scalability, this module provides a truly reproducible solution for CGT manufacturing processes.

In addition, Lonza will participate in the following two key events during the conference, and industry professionals are cordially invited to attend and engage in exchanges:

Subforum 4: Breakthrough Advances in Immune Cell Therapy for Autoimmune Diseases
Presentation Title:Process Innovation in Large-Scale Non-Viral T Cell Gene Editing: The Translation Pathway from Pilot-Scale to GMP Manufacturing
Speaker:Ma Shun, SME Expert, Lonza China

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Cell and Gene Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, applications, and market access information in the global cell and gene therapy sector, while facilitating connections between high-quality collaborative projects and overseas investors seeking investment opportunities. It aims to establish a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global supply chain.

The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, covering the latest advancements in global gene therapy, immune cell therapy, in vivo CAR-T, adult stem cells and exosomes, iPSC-derived cell therapies, small nucleic acid drugs, gene editing, oncolytic viruses, tumor vaccines, as well as clinical applications and breakthroughs, CMC and testing, AI-driven drug R&D, registration and regulation, and investment, financing, and BD matchmaking.Comprehensive Coverage Across the Entire Industry Chain.

2025 The 2nd China Society for Gene and Cell Therapy (CSGCT) Congress

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, please scan the QR code to visit the official conference website.